The benefit or harm of a single medication recommended for one specific condition can be difficult to determine in individuals with multiple chronic conditions and polypharmacy. There is limited information on the associations between guideline-recommended medications and physical function in older adults with multiple chronic conditions. The objective of this study was to estimate the beneficial or harmful associations between guideline-recommended medications and decline in physical function in older adults with multiple chronic conditions. DESIGN: Prospective observational cohort. SETTING: National. PARTICIPANTS: Community-dwelling adults aged 65 and older from the Medicare Current Beneficiary Survey study (N = 3,273). Participants with atrial fibrillation, coronary artery disease, depression, diabetes mellitus, or heart failure were included. MEASUREMENTS: Self-reported decline in physical function; guideline-recommended medications; polypharmacy (taking <7 vs ≥7 concomitant medications); chronic conditions; and sociodemographic, behavioral, and health risk factors. RESULTS: The risk of decline in function in the overall sample was highest in participants with heart failure (35.4%, 95% confidence interval (CI) = 26.3-44.5) and lowest for those with atrial fibrillation (20.6%, 95% CI = 14.9-26.2). In the overall sample, none of the six guideline-recommended medications was associated with decline in physical function across the five study conditions, although in the group with low polypharmacy exposure, there was lower risk of decline in those with heart failure taking renin angiotensin system blockers (hazard ratio (HR) = 0.40, 95% CI = 0.16-0.99) and greater risk of
N early three-quarters of adults aged 65 and older have multiple chronic conditions. 1 Because prescribing decisions for these persons tend to be made using clinical practice guidelines for individual conditions, 2 persons with multiple conditions take large numbers of medications. 3 Taking many medications is burdensome, increasing the likelihood of adverse drug effects. 4, 5 Furthermore, the benefit or harm of a medication prescribed for a single condition can be difficult to determine for an individual with multiple conditions. 6 A majority of older adults identify physical function as their most-important health outcome when faced with trade-offs regarding the benefits and harms of medications. 7 Understanding the effects of medications on multidimensional measures of function is necessary to improve medication decision-making.
Given the limited data on the benefits and harms of commonly prescribed guideline medications that older adults with multimorbidity and polypharmacy use, we examined the association between beta-blockers, nondihydropyridine calcium channel blockers (CCBs), renin angiotensin system (RAS) blockers, statins, metformin, and selective serotonin reuptake inhibitors (SSRIs) and physical function in a national sample of older adults with multiple chronic conditions. Potential benefits of these medications for physical function could occur through improvements in muscle strength, 8, 9 reductions in inflammation, 10, 11 or better glycemic control. 12 Potentially harmful effects on physical function could occur because of muscle weakness 13, 14 and orthostatic hypotension. 15, 16 We studied participants with at least one of five symptomatic conditions for which these medications are indicated: atrial fibrillation, coronary artery disease (CAD), depression, type 2 diabetes mellitus, and heart failure. Because polypharmacy has been shown to increase the likelihood of adverse drug events, hospitalization, falls, functional decline, and mortality, we estimated the association between each guideline medication and physical function stratified by polypharmacy.
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METHODS
Study Population
The combined sample included participants in the Medicare Current Beneficiary Survey (MCBS) study from five yearly panels drawn between 2005 and 2009. Each panel is followed for 3 years. The current study had follow-up data available from 2006 to 2011. MCBS is a nationally representative sample of Medicare beneficiaries obtained from the Centers for Medicare and Medicaid Services enrollment file. 18 Details on the study population are described elsewhere [19] [20] [21] ; briefly, we identified common chronic conditions (≥10% prevalence) associated with mortality and for which disease guidelines recommend at least one oral prescription drug that at least 10% of the final study cohort used. The final conditions included atrial fibrillation, CAD, depression, type 2 diabetes mellitus, heart failure, hyperlipidemia, and hypertension. Conditions were identified according to one or more inpatient or two other types of claims (outpatient, physician, skilled nursing, home health).
Participants for this study were aged 65 and older and had one or more of five common symptomatic chronic conditions (atrial fibrillation, CAD, depression, type 2 diabetes mellitus, heart failure (referred to hereafter as study conditions)) and one or more of the following chronic conditions: hyperlipidemia, hypertension, thromboembolic disease, and chronic kidney disease (referred to hereafter as coexisting conditions). We consider these five conditions as symptomatic because treatment is focused on affecting individuals' current functioning, whereas with asymptomatic conditions the focus is on prevention of future outcomes. 22 Of 19,043 MCBS community-dwelling participants, 2,682 were Medicare Advantage participants lacking claims data, 9,141 did not meet the condition criteria, 1,505 did not respond, and 277 lacked medication data at study entry, leaving 5,438 participants. We also excluded 2,165 participants who used equipment to walk or transfer from a bed or chair, resulting in a total sample size of 3,273. The Yale University Human Investigation Committee determined that the study was exempt because it involved existing, publicly available, deidentified data.
Outcome
At baseline and each annual follow-up, self-reported physical function was assessed by asking participants to rate their current level of difficulty in performing five activities (writing and handling objects; extending arms above shoulders; stooping, kneeling, and crouching; lifting and carrying 10 pounds; walking one-quarter of a mile or 2-3 blocks). 23 We created a count variable (0-5) reflecting the number of activities the participant was able to perform (at any level of difficulty). We defined the outcome "decline in function" as a decrease in the number of activities the participant was able to perform at follow-up. Participants who were unable to perform all five activities at baseline were excluded from the analysis (n = 8). Many studies have reported outcomes of acquiring an additional disability (change of 1 point) as a clinically meaningful change. 24 
Exposures
Medications
Commonly used medications listed in recent national disease guidelines for the five study conditions were examined. [25] [26] [27] [28] [29] These medications have plausible biological mechanisms for an adverse or beneficial effect on current physical function via muscle strength, 30, 31 inflammation, 32, 33 insulin resistance, 34, 35 arrhythmias, 36, 37 and orthostatic hypotension. 38 They include beta-blockers (cardio-selective or alpha/beta-blockers) 39 for atrial fibrillation, CAD, and heart failure; nondihydropyridine CCBs for atrial fibrillation 14 ; RAS blockers for CAD, diabetes mellitus, and heart failure 8, 9 ; statins for CAD and diabetes mellitus 13, 14 ; metformin for diabetes mellitus 40 ; and selective serotonin reuptake inhibitors (SSRIs) for depression. 16 Prescription medications were ascertained according to direct observation of medication containers at baseline and annual follow-up face-to-face interviews. Changes in medications were accounted for by updating the measures of prescription drug use annually. A polypharmacy measure was created based on the number of concomitant prescription medications (excluding the guideline-recommended medications under study) the participant was taking at baseline. A dichotomous measure of polypharmacy was defined as low polypharmacy for those taking fewer than seven concomitant prescription medications (the mean) and high polypharmacy for those taking seven or more concomitant prescription medications.
Covariates
Sociodemographic, behavioral, and health covariates were selected based on previously identified risk factors 41 and characteristics associated with medication exposure and included age; sex; race (nonwhite vs white); Hispanic ethnicity; income; number of concomitant prescription medications; prescription drug insurance coverage; days spent in the hospital in the year preceding follow-up (0, 1-6, ≥7); smoking; obesity (body mass index >30.0 kg/m 2 ); and hearing, vision, and cognitive impairments. Hearing impairment was defined as having a lot of trouble hearing or being deaf, and vision impairment was defined as having a lot of trouble seeing or being blind. Cognitive impairment was defined as a dementia or cognitive disorder claim or self-reported memory loss plus trouble concentrating or difficulty making decisions that interfered with activities of daily living. Coexisting study conditions (hyperlipidemia, hypertension, thromboembolic disease, and chronic kidney disease), osteoarthritis, and Elixhauser comorbidity scale 42 were included in the analyses. The guideline recommendation for atrial fibrillation is limited to nondihydropyridine CCBs. We also included dihydropyridine CCBs as a covariate rather than reduce our sample by excluding participants taking dihydropyridine CCBs. Finally, because use of insulin may reflect more-severe diabetes mellitus, we included this as a covariate in the analyses of participants with diabetes mellitus.
Statistical Analysis
To limit the estimation of associations between each guideline-recommended medication and decline in physical function to those with the condition for which the medication is indicated, five separate analytical samples were created for participants with atrial fibrillation, CAD, depression, diabetes mellitus, and heart failure. Baseline characteristics were summarized as frequencies and percentages or means and standard errors. The product-limit method was used to estimate the unadjusted proportion of participants who declined over follow-up. Because MCBS had annual interviews, an interval-censored timeto-event analysis using a complementary log-log link was estimated, with repeated observations for participants until the time of decline, dropout, death or end of followup, whichever occurred first. For each study condition model, time-varying main effects for the medications that the guidelines indicated for the condition were updated along with adjustment for the other coexisting conditions, medications, and covariates. These models yield hazard ratios (HRs) of the association between each guidelinerecommended medication and decline in physical function. Analyses were conducted for the overall sample and stratified according to polypharmacy. Interaction terms for polypharmacy group by guideline medication were included in the model to test for differences according to polypharmacy in the association between each study medication and decline in function.
Given the discrete time intervals, the competing risk of death could not be modeled using methods for continuous time. Instead, we performed sensitivity analyses by imputing the five missing function items for those who died under assumptions of missing at random (MAR) and missing not at random (MNAR). For MNAR, we examined the effect of adding bias by increasing the proportion who were unable to perform each item among the values imputed for decedents, using the SAS PROC MI procedure. 43 Multiple imputation with 10 replicates was used for missing medication (at follow-up), which was less than 1%, and for covariate data, which was less than 1.9%, using SAS/STAT PROC MI and MIANALYZE. We used SAS version 9.4 (SAS Institute, Inc., Cary, NC), with P < .05 (two-tailed) used to denote statistical significance.
RESULTS
Characteristics of the participants in the five study condition groups are shown in Table 1 . Because participants could have multiple study conditions, we did not statistically compare the groups. The most-prevalent chronic conditions were hypertension (90.0-95.9%), hyperlipidemia (77.3-91.2%), and osteoarthritis (51.5-59.7%), and the average number of Elixhauser comorbidities was highest in those with heart failure (2.6, SE (0.08)) and lowest in those with diabetes mellitus (1.3, SE (0.04) ). The mean number of concomitant medications ranged from 6.6 (SE 0.17) in those with atrial fibrillation to 8.2 (SE 0.21) in those with heart failure.
Multimorbidity was common. The majority of participants with heart failure and atrial fibrillation had CAD, 68.6% and 54.2% respectively, whereas diabetes mellitus co-occurred with the other conditions in approximately one-third of participants (32.1-45.3%).
More than 78% of the participants received at least one guideline-recommended medication, with the exception of SSRIs (40.8%) ( Table 2) . Percentages receiving the individual medications recommended for each condition, ranged from 15.2% for nondihydropyridine CCBs to 71.8% for beta-blockers.
The majority of participants were able to perform all five activities at baseline, ranging from 77.9% to 85.0% across study condition (Table 2) . Participants in the high polypharmacy group were less likely to be able to perform all five activities at baseline than those in the low polypharmacy group.
The percentage of those who declined in the overall sample and stratified according to polypharmacy is shown at the bottom of Table 2 . In the overall sample, decline was highest in participants with heart failure (35.4%, 95% CI = 26.3-44.5) and lowest in those with atrial fibrillation (20.6%, 95% CI = 14.9-26.2). Decline was substantially greater for those in the high polypharmacy group that for those in the low polypharmacy group for participants with CAD, diabetes mellitus, and heart failure. Although participants in the high polypharmacy group were more disabled at baseline and subsequently had less chance of decline, decline was greater for those taking more medications with the exception of participants with depression. Decrease in number of activities participant was able to perform from baseline. Respondents who could not perform any of the five activities were excluded because they could not decline. Product-limit estimates. Figure 1 displays the adjusted HRs (aHRs) for each medication according to study condition, reflecting the risk of decline in physical function over follow-up for those taking the medication relative to those not taking the medication. There were no statistically significant associations between any of the guideline-recommended medications and risk of decline in function.
The results stratified according to low and high polypharmacy are displayed in Figure 2 . There were two significant interactions reflecting differences in the association between medication and function according to polypharmacy. For participants with heart failure in the low polypharmacy group, RAS blockers were associated with lower risk of decline in function (aHR = 0.40, 95% CI = 0.16-0.99), whereas there was no association in the high polypharmacy group (aHR = 1.14, 95% CI = 0.67-1.95). The interaction of polypharmacy and statins was also significant, with greater risk of decline in participants with diabetes mellitus in the low polypharmacy group (aHR = 2.27, 95% CI = 1.39-3.69) versus no association in the high polypharmacy group (aHR = 0.77, 95% CI = 0.54-1.10). The association for statins remained significant (aHR = 2.09, 95% CI = 1.24-3.52) when excluding insulin users. Finally, to check the sensitivity of the results to the cut-point used for polypharmacy, the same interactions were significant using the continuous number of concomitant medications.
We considered the possibility that differences in baseline functional status might influence these findings. When we limited the analysis to those who could perform all five tasks at baseline, the findings did not meaningfully differ. For example, the interactions between polypharmacy and RAS blockers in participants with heart failure (interaction P = .02) and statins in participants with diabetes mellitus (interaction P = .01) remained significant. The adjusted hazard ratio for RAS blockers was 0.41 (95% CI = 0.16-1.00), while the adjusted hazard ratio for statins was 2.33 (95% CI = 1.40-3.87) in the low polypharmacy group.
When we conducted sensitivity analyses to assess bias due to deaths we observed similar findings for the associations between each medication and function, although for those with heart failure in the low polypharmacy group, The displayed hazard ratios reflect the effect taking the medication for a specific condition versus not taking the medication and are adjusted for the covariates (demographic characteristics, insurance, geriatric impairments, health behaviors, hospitalizations, medications (other guideline-recommended and number of concomitant), the other study conditions, and Elixhauser comorbidity scale. Decline in physical function was defined as a decrease in the number of activities (writing and handling objects; extending arms above shoulder; stooping, kneeling, or crouching; lifting or carrying 10 pounds; walking one-quarter of a mile or 2-3 blocks) the participant was able to perform from baseline. Eight respondents who could not perform any of the five activities were excluded because they could not decline.
the reduction in decline associated with RAS blockers lost significance when the risk of decline in the 27 deceased participants was assumed to range from 15% to 90% in the multiple imputation analysis. 43 
DISCUSSION
Although there are multiple mechanisms by which the six guideline-recommended medication classes in this study may have positive or negative effects on physical function, none of these medications was significantly associated with decline in physical function in the overall sample. In participants with low polypharmacy, RAS blockers were associated with lower risk of decline in those with heart failure, whereas statins were associated with greater risk of decline in those with diabetes mellitus. Some studies suggest that aldosterone blockade may reduce decline in physical function by reducing muscle strength, but the majority of studies on the RAS have examined angiotensin-converting enzyme inhibitor (ACE-I) use. 8 Two investigations provide some evidence of a reduction in disability, exercise capacity, and muscle strength directly, and a review of studies showed a beneficial effect of ACE-Is and angiotensin receptor blockers on exercise capacity, although the exact mechanisms are unclear. 9, 44, 45 Our results indicated a protective association between RAS blockers and risk of decline but only in the low polypharmacy group, although sensitivity analysis showed that, if 15% or more of the decedents had declined, then the protective association lost significance, suggesting that this result is not robust to losses due to death.
For statins, studies examining various measures of physical function have mixed findings. One study 46 found that statins were associated with better self-reported physical function but not a summary performance measure of walking, chair rises, dressing, and a tandem stand. Another study reviewed possible mechanisms and suggested that, by reducing cardiovascular events, performance was maintained, in addition to the possibility that statins may reduce inflammation and the resultant effect on disability, 10 although another study found no association between statins and incident mobility limitation (walking one-quarter of a mile or climbing 10 steps without resting) over 6.5 years of follow-up. 47 Our finding that there was an association between risk of decline in physical function for participants with diabetes mellitus taking statins in the low polypharmacy group but no difference in the high polypharmacy group deserves further study. Because we Figure 2 . Adjusted hazard ratios for decline in physical function by guideline-recommended medication and condition stratified according to low (<7 concomitant medications) and high (≥7 concomitant medications) polypharmacy. The displayed hazard ratios reflect the effect of taking the medication for a specific condition versus not taking the medication and are adjusted for the covariates (demographic characteristics, insurance, geriatric impairments, health behaviors, hospitalizations, medications (other guideline-recommended and number of concomitant), the other study conditions, and Elixhauser comorbidity scale. Decline in physical function was defined as a decrease in the number of activities (writing and handling objects; extending arms above shoulder; stooping, kneeling, or crouching; lifting or carrying 10 pounds; walking one-quarter of a mile or 2-3 blocks) the participant was able to perform from baseline. Eight respondents who could not perform any of the five activities were excluded because they could not decline.
restricted our sample to participants with conditions (e.g., diabetes mellitus) indicated for prescribing statins, whereas many studies use samples of participants who may not have an indicated condition for statins, it is difficult to compare findings. Finally, when we accounted for the deaths, the association between statins and greater risk of physical decline was still present, even when the outcome risk in decedents was inflated from 14% to 99%.
There are strengths, as well as weaknesses, in using an observational design to examine the associations between medications and physical function. The large nationally representative sample of older adults with MCC provides information on a population often excluded from randomized controlled trials, and the physical function outcomes are well validated and of high importance to older adults yet rarely considered in clinical trials. Medication use was ascertained according to direct examination of containers.
We adjusted for a wide range of time-varying characteristics, including important medical conditions such as osteoarthritis, psychosocial measures, and geriatric impairments, which may influence prescribing of the study medication and functional outcomes. Multiple imputation analysis was used to address the potential bias due to missing data (<1.9%), and we conducted a sensitivity analyses to assess the effect of losses due to death.
As in any observational study, we cannot infer causal relationships. Although a wide range of covariates was adjusted for, we cannot eliminate the possibility of confounding by other unmeasured covariates that may have biased our results. We also conducted several statistical tests, increasing the probability of finding an association by chance. We were limited to self-reported physical function, which reflects participants' perceptions of their abilities and not necessarily an objective performance-based measure of function. We examined whether baseline polypharmacy exposure, measured according to the number of concomitant medications, modified the associations between individual guideline-recommended medications and physical function, but number of medications alone cannot be used to inform prescribing decisions. 48 The observed reduction in risk of decline in function associated with RAS blockers in the low polypharmacy group could reflect a healthy user bias, because those taking fewer medications may be healthier and more likely to benefit from the medication, although this would not explain the greater risk associated with statins in those taking fewer medications. An additional limitation is that the significant interactions between polypharmacy, statins, and RAS blockers were not specified a priori, so they should be interpreted with caution.
We could not include participants in Medicare Advantage plans because they do not have healthcare claims. Furthermore, our sample reflects higher-functioning older adults since we excluded those needing assistive devices as the majority were unable to perform the activities we assessed. This group is an important segment of the population of older adults and brings attention to the need to study universal cross-disease outcomes including perceived health, symptoms, and social or recreational activities to determine benefits and harms of medications in this subgroup. 49 Finally, we did not have information on when chronic conditions began, medication dose, or treatment duration.
Despite these limitations, our study suggests that, with a few exceptions among those taking fewer concomitant medications, the use of guideline medications is not associated with decline in physical function in a high-functioning sample of older adults.
